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Summary 
We compared sequential single-agent BCNU and procarbazine (PCB) chemotherapy in 31 patients with glio- 
mas [grade IV (10), grade III (15), grade II (6)]. Patients had failed surgical biopsy+ resection and radiation 
therapy. All patients were treated initially with BCNU 150-300mg/m 2 by intra-arterial or intravenous route 
every 6 weeks. After CT evidence of tumor progression, all patients received PCB 150mg/m2/day for 28 days 
every 8 weeks. Patient responses to BCNU were CR (0), PR (7), SD (12), progression (12), and to PCB CR (2), 
PR (9), SD (6), and progression (14). Kaplan-Meier estimates of median time to failure for all patients were 
shorter for BCNU, 5.0 months (range 1.5-20), than for PCB, 6.0 months (range 2-50+). There was a statistical- 
ly significant difference (Mantel-Cox test, p = 0.02) in the distribution of time to disease progression between 
the two drugs, especially for grade III tumors (p-- 0.02). The cumulative proportion of patients without dis- 
ease progression at 6 months was 26% while on BCNU, compared to 48% while on PCB; at 12 months the 
cumulative proportions were 3 % for BCNU compared to 35 % for PCB. Although there was no formal wash- 
out period between administration of the two drugs, no carryover effect was evident. These data provide 
further evidence that PCB has significant activity against malignant glioma and may, in fact, be more effective 
than BCNU. 
Introduction 
Malignant gliomas are the most common primary 
central nervous sytem (CNS) neoplasms of adult- 
hood and remain refractory to therapy. Despite ad- 
vance in neurosurgical and radiotherapeutic tech- 
niques, median survival after these treatment mod- 
alities is only 37 weeks [1]. The addition of 1,3-bis(2- 
chloroethyl)-l-nitrosourea (BCNU) as single-agent 
chemotherapy after radiation therapy (RT) extends 
median survival to 50-51 weeks [2, 3]. BCNU re- 
mains the standard of comparison for single-agent 
and combination chemotherapy regimens, despite 
its modest efficacy [4]. 
Procarbazine (PCB) is an alkylating agent with 
activity against many neoplasms, including gliomas. 
In a prospective randomized trial comparing 
BCNU and PCB as adjunctive treatment after RT, 
median survival was similar [3]. Reports of the effi- 
cacy of PCB when used as a single agent after RT 
and nitrosourea failure vary [5, 6]. 
To further clarify the effectiveness of PCB 
against malignant glioma, we analyzed data from 
our previously reported patient group [6] and com- 
pared responses between sequentially adminis- 
tered single-agent BCNU and PCB. In this report 
we describe the results of this comparison. 
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Materials and methods 
Thirty-one consecutive patients (19 male, 12 fe- 
male) who had initially received BCNU and were 
subsequently treated with PCB were studied. The 
mean age at initiation of chemotherapy was 39.5 
and 40.4 years, respectively, for BCNU and PCB. 
Twenty-five patients had complete or subtotal re- 
sections; 6 underwent only biopsy. All tumors were 
graded using the Kernohan classification. Six pa- 
tients had low grade astrocytoma (grade II), 15 had 
anaplastic astrocytoma (grade III), and 10 had glio- 
blastoma multiforme (GBM, grade IV). All pa- 
tients had received 5,500-6,500cGy of whole brain 
Table 1. Patient  responses to therapy with B C NU and PCB 
external beam radiation therapy with a focal boost 
to the tumor bed before BCNU. 
Patients were initially treated with BCNU, 18 re- 
ceiving it intra-arterially (IA, 150-200mg/m 2 every 
6 weeks), 9 intravenously (250-300mg/m 2 every 6 
weeks), 4 receiving both IA and IV treatment. Af- 
ter demonstration by cranial CT of tumor progres- 
sion (performed every 6 weeks or as needed), all 
patients were placed on oral procarbazine, 150rag/ 
m2/d for 28 days every 8 weeks, the standard PCB 
dosing regimen as described by Green et al. [3]. 
While on PCB, patients received cranial CT or MRI 
every 8 weeks or as needed. Three patients received 
and failed other chemotherapy before starting PCB 
Patient Grade B C N U  Rte B C NU PCB 
3 II IV P R  12 (mo.) PD 2 (mo.) 
8 II IA PD 3 PR  12+ 
12 II IV P R  8 PR  13 
16 II IA/IV P R  8 PD 2 
21 II IV SD 7 SD 13+ 
23 II IA SD 6 PR  50+ 
1 III IA SD 5 PD 4 
2 III IV PD 4 PD 2 
4 III IV SD 5 CR 11 
6 III IA SD 11 PD 2 
7 III IA SD 5 PD 4 
14 III IA SD 5 PD 2 
18 III IA PD 3 SD 6 
22 III IA PD 4 SD 12+ 
24 III IA PD 3 PR  24+ 
25 III IV P R  20 SD 44+ 
26 III IA SD 6 SD 46+ 
27 III IA/IV SD 5 CR 12+ 
28 III IV PD 5 PR  32+ 
29 III IA PD 3 PR  30 
31 III IA PD 3 PR 10 
5 IV IA SD 5 PD 2 
9 IV IV PD 3 PD 2 
10 IV IA PD 3 PR  7 
11 IV IA P R  8 PR  6 
13 IV IV P R  8 PD 2 
15 IV IA PD 3 PD 4 
17 IV IA PD 2 PD 4 
19 IV IA/IV SD 9 SD 8 
20 IV IA SD 5 PD 2 
30 IV IA/IV PD 3 PD 2 
Response  Durat ion Response  Durat ion 
(2 receiving IA cisplatin and I receiving IA diaziqu- 
one). Treatment with cisplatin or diaziquone was 
brief (1,1, and 4 months) and terminated after une- 
quivocal CT or MRI progression. 
Response criteria were as follows: Complete Re- 
sponse (CR), complete resolution of all abnormal- 
ities suggestive of tumor on CT scan and a stable or 
improved neurologic examination without steroids; 
Partial Response (PR), greater than a 25% de- 
crease in tumor size on CT scan plus a stable or im- 
proved neurologic examination on a stable or re- 
duced dose of steroids; Stable Disease (SD), no 
change in tumor size on CT scan, without significant 
change in neurologic examination while on stable 
or decreasing doses of steroids for at least 2 cycles of 
chemotherapy; Progressive Disease (PD), greater 
than 25% increase in tumor size on CT scan and/or 
progressive worsening of neurologic function di- 
rectly attributable to growth of the tumor. The du- 
ration of response dated from the onset of treat- 
ment until demonstration of disease progression. 
For the purposes of this study, responses were con- 
sidered to be Complete Response+ Partial Re- 
sponse+ Stable Disease. 
Kaplan-Meier estimates of time to failure were 
calculated, and the Mantel-Cox test was used to 
compare the failure time distributions, ignoring the 
natural pairing of observations. The Wilcoxon 
signed-rank test for paired data also was used to 
compare time to progression, treating as failure 
times the 9 censored times of patients whose disease 
had not yet progressed. 
Results 
Patient responses to BCNU and PCB therapy are 
shown in Table 1. When response was defined as 
Complete Response+ Partial Response+ Stable 
Disease there was no statistically significant differ- 
ence in proportion of patients responding to BCNU 
compared to PCB (McNemar's test, p ;  0.62). Ten 
patients responded to both regimens, and 5 patients 
had PD on both regimens; nearly equal numbers 
had disease that progressed on one regimen but not 
on the other (7 with Partial Response or Stable Dis- 
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Fig. 1. Kaplan-Meier curve of time to progression for patients 
after receiving BCNU of PCB (p = 0.02). 
with Partial Response or Stable Disease on BCNU 
had Progressive Disease on PCB). The conclusions 
are unchanged if we compare Complete Response + 
Partial Response to Stable Disease+ Progressive 
Disease (McNemar's test, p = 0.25). 
The rate of Complete Response+ Partial Re- 
sponse for PCB was 35% (2 CR, 9 PR) compared to 
23% (0 CR, 7 PR) for BCNU. Thirty-five percent of 
patients (11/31) had the same or better response to 
PCB compared to the response to BCNU. Of the 12 
patients with progressive disease on BCNU, 5 had a 
Partial Response and 2 had Stable Disease while on 
PCB. 
Time to disease progression was significantly 
longer for the PCB regimen than for the BCNU re- 
gimen, whether a paired analysis (Wilcoxon test, p = 
0.05) or an unpaired analysis (Mantel-Cox test, p = 
0.02) was used (Fig. 1). The cumulative proportion 
of patients without disease progression at 6 months 
was 26 % while on B CNU and 49 % while on PCB; at 
12 months, the cumulative proportions were 3 % for 
BCNU and 35% for PCB. Median time to progres- 
sion was 5 months (range 2-20 months) on BCNU 
and 6 months (range 2-50+ months) on PCB. 
Twenty-six of the 31 patients in the study respon- 
ded (CR, PR, or SD) to either BCNU, PCB, or both 
(6/6 grade II, 14/15 grade IfI, 6/10 grade IV). When 
the responders were analyzed separately, the statis- 
tical significance of the difference in survival disti- 
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butions was more pronounced (Wilcoxon test, p = 
0.03, Mantel-Cox, p= 0.01). Median time to pro- 
gression was unchanged, 5 months, for BCNU but 
increased to 8 months for PCB. 
Although the number of patients is relatively 
small, we also considered whether the difference in 
time to progression was associated with either tu- 
mor grade or route of BCNU administration. Time 
to progression for patients with grade III tumors on 
PCB was significantly greater than time to progres- 
sion for patients with grade III tumors on BCNU 
(Mantel-Cox test, p = 0.02; median of 4.5 months on 
BCNU compared to 10.5 months on PCB). There 
was no statistically significant difference in time to 
progression for patients with grade IV tumors 
(Mantel-Cox test, p= 0.41) or grade II tumors 
(Mantel-Cox test, p = 0.18). More than half of the 
patients in the study received IA BCNU. For these 
patients, time to progression was significantly long- 
er for the PCB regimen than for the BCNU regimen 
(Mantel-Cox test, p= 0.03). The differences be- 
tween BCNU and PCB were not statistically signif- 
icant for patients who received IV BCNU (Mantel- 
Cox test, p= 0.38) or IA and IV BCNU (Mantel- 
Cox test, p = 1.0). 
Toxicity was divided into nonhematologic and 
hematologic categories. Patients receiving BCNU 
developed the following nonhematologic complica- 
tions: mild nausea in most patients, leukoencepha- 
lopathy (1), and retinopathy (3). There were no epi- 
sodes of pulmonary fibrosis. Patients receiving PCB 
also developed frequent nausea, as well as fatigue 
(6), herpes zoster (7), and rash (1). Hematologic 
toxicity in patients receiving BCNU was relatively 
mild. The majority of patients developed mild leu- 
kopenia (<3000, >1500) and thrombocytopenia 
(<150,000, >50,000). One patient (#8) developed 
severe thrombocytopenia (<50,000) after IA 
BCNU and required platelet transfusions, but did 
not have any hemorrhagic episodes. No infectious 
complications were noted in the BCNU patients. 
The hematologic complications for patients receiv- 
ing PCB were more severe. Six patients developed 
severe leukopenia (< 1500), and 5 developed severe 
thrombocytopenia; there were no infectious or 
hemorrhagic complications. 
Discussion 
Many chemotherapeutic agents have been used to 
treat malignant gliomas. The majority of these 
agents, either alone or in combination, have not 
proved effective. Randomized trials [1--4] have 
demonstrated the efficacy of BCNU, and it is gener- 
ally regarded as the preferred chemotherapy drug 
for gliomas [7]. Several reports [3, 6] suggest that 
single-agent PCB is also effective against malignant 
glioma and may be as effective as BCNU, although 
other studies have not been as favorable [5]. PCB 
demonstrated a nonsignificant trend toward longer 
survival at 18 and 24 months compared to BCNU in 
the study by Green et al. [3]. Rodriguez et al. [5] 
studied 83 patients with recurrent malignant glioma 
and had an overall response rate of only 28%. In the 
study by Newton et al. [6], 35 patients treated with 
PCB showed an overall response rate of 57%. PCB 
dosing and patient demographics were comparable 
in the studies of Rodriguez and Newton, except for 
a somewhat larger percentage of GBM patients 
(45% vs 34%) in the Rodriguez study. In this study, 
we compared responses to BCNU and PCB in a co- 
hort of patients receiving both drugs. Time to pro- 
gression was significantly longer for PCB than 
BCNU (p= 0.02, Fig. 1), although the two agents 
had nearly identical response rates: CR+ PR+ SD 
was 55% for PCB and 61% for BCNU, while the 
CR+ PR rate was 35% for PCB compared to 23% 
for BCNU; the differences were not statistically sig- 
nificant (p> 0.25). The majority of patients (68%) 
had the same or better response to PCB than 
BCNU. The difference in response was most appa- 
rant for grade III patients, who had a significantly 
longer time to progression (p = 0.02) while on PCB 
as compared to BCNU. This data provides further 
evidence that PCB is efficacious treatment for pa- 
tients with malignant glioma and may be more ef- 
fective than BCNU. 
For patients receiving PCB after failure of IA 
BCNU, the time to disease progression was signif- 
icantly longer (p= 0.03) than for those who had 
failed IV or IA/IV BCNU. The cause of this rela- 
tionship is unclear, but does not appear to be relat- 
ed to the distribution of histologic types among the 
routes of BCNU administration. Ten of the 15 grade 
III tumors (66%) and 6 of the 10 grade IV tumors 
(60%) received IA BCNU. The improved response 
duration of PCB was not related to more severe tox- 
icity in the IA BCNU patient group, as recently re- 
ported by Shapiro et al. [8]. In their randomized 
study, grade III patients who received IA BCNU 
had reduced survival (p= 0.002) and more signifi- 
cant toxicity when compared to patients treated 
with IV BCNU. Toxicity consisted of irreversible 
encephalopathy, cerebral edema, and visual loss. 
Few of our patients demonstrated this toxicity by 
clinical or neuroimaging criteria and were consid- 
ered BCNU failures only on the basis of enlarge- 
ment of enhancing tumor mass on CT scan. 
Procarbazine requires activation to intermediate 
forms before developing potent antineoplastic ac- 
tivity [9, 10]. It is first metabolized into an azo-PCB 
derivative, which has similar potency to PCB. Fur- 
ther metabolism by the cytochrome P-450 system 
converts azo-PCB into two seperate azoxy-PCB de- 
rivatives, which have significantly greater antitu- 
mor activity than PCB or azo-PCB. The azoxy-2- 
PCB derivative is the most active metabolite of 
PCB and causes cell death by inducing DNA strand 
breaks. Activated PCB, like BCNU, also derives 
some of its antitumor activity from alkylation of 
DNA, placing adducts onto the 06 position of gua- 
nine [11,12]. The enzyme O6-alkylguanine-DNA al- 
kyltransferase (AT) repairs DNA by removing the 
adducts of BCNU and PCB, thus reducing subse- 
quent toxicity [11-13]. Tumor cells with high con- 
centrations of AT are more resistant to BCNU [14] 
and PCB [12]. Tumors that have progressed during 
BCNU treatment may have developed a resistant 
clone of cells with high levels of AT [15]. These cells 
might also demonstrate cross-resistance to PCB. 
This scenario would theoretically militate against 
using PCB sequentially after BCNU. It is therefore 
surprising that our patients responded so well to 
PCB after BCNU failure. This suggests that the 
mechanism of BCNU resistance was not elevated 
concentration of AT, but instead may have been re- 
duced cell uptake or accelerated inactivation of 
BCNU by cellular components such as glutathione 
[16]. 
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Several newer studies utilizing PCB as part of 
multi-agent chemotherapy regimens for malignant 
glioma also suggest treatment alternatives to con- 
ventional BCNU [17,18]. In a randomized prospec- 
tive trial by Levin et al. [17] comparing adjuvant 
BCNU to procarbazine, lomustine, and vincristine 
(PCV), PCV was significantly more effective than 
BCNU in terms of overall survival (p= 0.021) and 
time to progression (p= 0.025) for patients with 
anaplastic astrocytoma. The current study corrob- 
orated some of their findings, in that single-agent 
PCB demonstrated significantly longer time to pro- 
gression compared to BCNU (p= 0.02) for treat- 
ment of anaplastic astrocytoma, but not glioblasto- 
ma multiforme. In a phase II trial [18] etoposide, 
vincristine, and procarbazine were used against ma, 
lignant glioma, with a mean time to progression of 
46 weeks. Our data would suggest that PCB is the 
most active and important agent in these combina- 
tion regimens and that the effectiveness of both re- 
gimens might be further improved with larger PCB 
doses. More novel approaches to chemotherapy, 
such as interstitial implantation of drug polymer 
wafers [19, 20] or hi-dose chemotherapy in combi- 
nation with hematopoietic growth factors [21], also 
hold promise as alternative methods of treatment. 
The statistical methods used to analyze the data 
have some limitations. Because each patient re- 
ceived both BCNU and PCB, paired analyses were 
used whenever possible. The Wilcoxon signed-rank 
test for paired data was used to compare time to 
progression, ignoring the fact that 9 patients have 
censored times to progression on PCB. Since none 
of the times to progression on BCNU are censored 
and all of the censored times on PCB are greater 
than the corresponding times to progression on 
BCNU, the results would be more strongly in favor 
of PCB if there were no censoring. No formal wash- 
out period was allowed between progression on 
BCNU and initiation of PCB therapy, thereby mak- 
ing it impossible to determine if carryover effects of 
BCNU affected results observed with PCB. Be- 
cause of each patient's unequivocal progression 
during BCNU therapy, we assumed carryover ef- 
fects were minimal and that time to progression fol- 
lowing PCB was independent of residual effects of 
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BCNU.  Carryover  effects of  radiat ion therapy 
might  have influenced the responses no ted  with 
BCNU,  but  were probably  of  minimal significance. 
If  present,  radiat ion carryover  effects would  have 
biased B C N U  responses  to appear  more  significant 
than they actually were, making the compar i son  to 
PCB responses even more  significant. 
Analysis  of  the responding versus non-respon-  
ding groups  also has limitations. It is possible that  
unmeasured  factors that  affect prognosis  and re- 
sponse to t rea tment  m a y  have influenced the re- 
sults, unre la ted  to the effects of  t reatment .  How-  
ever, each pat ient  received both  B C N U  and PCB 
sequentially, acting as his own control.  This should 
have minimized the effects of  unmeasured  varia- 
bles on outcome.  
Single and mult i -agent  chemothe rapy  regimens 
have p roduced  modes t  improvements  in survival as 
adjunctive therapy for  mal ignant  gliomas. B C N U  
remains the s tandard  of  compar i son  for  new che- 
m o t h e r a p y  protocols .  This paper  has demons t ra t ed  
that  PCB has significant activity in patients with 
malignant  glioma, and may  be more  effective than 
BCNU,  part icularly when time to failure is com- 
pared  in responders.  Grade  I I I  tumors  appear  to be 
the mos t  sensitive, but  PCB also demonst ra tes  ac- 
tivity against grade I I  and IV  tumors.  A randomized  
control led clinical trial with drug crossover  would  
be necessary to prove  that  PCB is a more  effective 
agent  than BCNU.  Using this design, with t ime to 
progress ion as the dependen t  variable instead of  
survival, would allow for  compar i son  of  upfront  ac- 
tivity of  bo th  drugs, as well as efficacy after progres-  
sion. In terac t ion  be tween  drugs could also be accu- 
rately analyzed.  
Acknowledgements 
This s tudy was suppor ted  in par t  by funding f rom 
N I H  grant  # M O I R R 0 0 0 4 2 .  
The  authors  would  like to thank Mr. David  Car- 
pen te r  of The  Ohio  State Univers i ty  for editorial 
assistance and the staff of  the Univers i ty  of  Michi- 
gan Clinical Research  Cente r  for their excellent pa- 
tient care. 
References 
1. Walker M, Alexander E, Hunt WE, MacCarty CS, Mahaley 
MS, Mealey J, Norrell HA, Owens G, Ransohoff J, Wilson 
CB, Gehan EA, Strike TA: Evaluation of BCNU and/or ra- 
diotherapy in the treatment of anaplastic glioma. J Neuro- 
surg 49: 333-343, 1978 
2. Walker MD, Green SB, Byar DR Alexander E, Batzdorf U, 
Brooks WH, Hunt WE, MacCarty CS, Mahaley MS, Mealey 
J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith 
KR, Wilson CB, Strike TA: Randomized comparisons of ra- 
diotherapy and nitrosoureas for the treatment of malignant 
glioma after surgery. NEJM 303: 1323-1329, 1980 
3. Green SB, Byar DR Walker MD, Pistenmaa DA, Alexander 
E, Batzdorf U, Brooks WH, Hunt WE, Mealey J, Odom GL, 
Paoletti R Ransohoff J, Robertson JT, Selker RG, Shapiro 
WR, Smith KR, Wilson CB, Strike TA: Comparisons of car- 
mustine, procarbazine, and high-dose methylprednisolone 
as additions to surgery and radiotherapy for the treatment of 
malignant glioma. Cancer Treat Rep 67: 121-132, 1983 
4. Shapiro WR, Green SB, Burger PC, Mehaley MS, Selker 
RG, VanGilder JC, Robertson JT, Ransohoff J, Mealey J, 
Strike TA, Pistenmaa DA: Randomized trial of three che- 
motherapy regimens and two radiotherapy regimens in 
postoperative treatment of malignant glioma. Brain Tumor 
Cooperative Group Trial 8001. J Neurosurg 71: 1-9, 1989 
5. Rodriguez LA, Prados M, Silver R Levin VA: Reevaluation 
of procarbazine for the treatment of recurrent malignant 
central nervous system tumors. Cancer 64: 2420-2423, 1989 
6. Newton HB, Junck L, Bromberg J, Page MA, Greenberg 
HS: Procarbazine chemotherapy in the treatment of recur- 
rent malignant astrocytomas after radiation and nitrosourea 
failure. Neurology 40: 1743-1746, 1990 
7. Kornblith PL, Walker M: Chemotherapy for malignant glio- 
mas. J Neurosurg 68: 1-17, 1988 
8. Shapiro WR, Green SB, Burger PC, Selker RG, VanGilder 
JC, Robertson JT, Mealey J, Ransohoff J, Mahaley MS: A 
randomized comparison of intra-arterial versus intravenous 
BCNU, with or without intravenous 5-fluorouracil, for new- 
ly diagnosed patients with malignant glioma. J Neurosurg 
76: 772-781, 1992 
9. Shiba DA, Weinkam RJ: The in vivo cytotoxic activity of 
procarbazine and procarbazine metabolites against L1210 
ascites leukemia cells in CDF 1 mice and the effects of pre- 
treatment with procarbazine, phenobarbital, diphenylhy- 
dantoin, and methylprednisolone upon in vivo procarbazine 
activity. Cancer Chemother Pharmaco111: 124-129, 1983 
10. Erikson JM, Tweedie D J, Ducore JM, Prough RA: Cytotox- 
icity and DNA damage caused by the azoxy metabolites of 
procarbazine in L1210 tumor cells. Cancer Res 49: 127--133, 
1989 
11. Brent TP, Houghton PJ, Houghton JA: O6-Alkylguanine - 
DNA alkyltransferase activity correlates with the ther- 
apeutic response of human rhabdomyosarcoma xenografts 
to .1- (2-chloroethyl)-3-(tr ans-4-methylcyclohexyl)-l-nitro- 
sourea. Proc Natl Acad Sci USA 82: 2987, 1985 
12. Schold SC, Brent TP, von Hofe E, Friedman HS, Mitra S, 
Bigner DD, Swenberg JA, Kleihnes P: O6-Alkylguanine - 
DNA alkyltransferase and sensitivity to procarbazine in hu- 
man brain-tumor xenografts. J Neurosurg 70: 573-577,1989 
13. Robins R Harris AL, Goldsmith I, Lindahl T: Cross-linking 
of DNA induced by chloroethylnitrosourea is prevented by 
O6-methylguanine-DNA methyltransferase. Nucleic Acids 
Res 11: 7743-7758, 1983 
14. Bodell WJ, Aida T, Berger MS, Rosenblum ML: Increased 
repair of O6-alkylguanine DNA adducts in glioma-derived 
human cells resistant to the cytotoxic and cytogenetic effects 
of 1,3-bis(2-chloroethyl)-l-nitrosourea. Carcinogenesis 7: 
879-883, 1986 
15. Shapiro WR, Shapiro JR: Principles of brain tumor chemo- 
therapy. Seminars Onc 13: 56-69, 1986 
16. Ali-Osman F: Quenching of DNA cross-link precursors of 
chloroethylnitrosoureas and attenuation of DNA inter- 
strand cross-linking by glutathione. Cancer Res 49: 5258- 
5261, 1989 
17. Levin VA, Silver R Hannigan J, Wara WM, Gutin PH, Davis 
263 
RL, Wilson CB: Superiority of post-radiotherapy adjuvant 
chemotherapy with CCNU, procarbazine, and vincristine 
(PCV) over BCNU for anaplastic gliomas: NCOG 6G61 fi- 
nal report. Int J Radiation Oncol Biol Phys 18: 321-324,1990 
18. Hellman RM, Calogero JA, Kaplan BM: Etoposide 
(VP-16), vincristine, and procarbazine in recurrent and pri- 
mary gliomas. Proc ASCO 9: 93,1990 
19. Brem H, Mahaley S, Vick NA, Black KL, Schold SC, Burger 
PC, Friedman AH, Ciric IS, Etler TW, Cozzens JW, Kenealy 
JN: Interstitial chemotherapy with drug polymer implants 
for the treatment of recurrent gliomas. J Neurosurg 74: 441- 
446, 1991 
20. Tomita T: Interstitial chemotherapy for brain tumors: re- 
view. J Neuro-Onco110: 57-74, 1991 
21. Andreef M, Welte K: Hematopoietic colony-stimulating 
factors. Seminars Oncol t6: 211-229, 1989 
Address for offprints: H.S. Greenberg, Department of Neurol- 
ogy, 1914/0316 Taubman Center, University of Michigan Hospi- 
tals, Ann Arbor, MI 48109-0316, USA 
